GLP-1 Medicaid Coverage by State: Anti-Obesity Medication Access (2026)
Key Findings
- As of April 2026, 13 state Medicaid fee-for-service programs cover GLP-1 medications for obesity or weight management — 10 with full coverage, 3 with restricted access. Source: KFF Medicaid GLP-1 Tracker (Jan 2026), verified against state formularies
- Only 19.7% of adult Medicaid enrollees live in states with a pathway to GLP-1 obesity coverage — approximately 7.8 million adults out of 39.5 million nationally. Source: The RX Index analysis of CMS adult enrollment data × KFF/state formulary coverage status
- 80.3% of adult Medicaid enrollees — over 31.7 million adults — live in states with no GLP-1 obesity coverage through Medicaid FFS. Source: The RX Index Coverage Reach calculation
- 35.0% of all adult Medicaid enrollees were affected by coverage changes in the past 12 months — including California (8.0M adults) and Pennsylvania (1.6M adults) dropping coverage, and North Carolina (1.4M adults) reinstating it. Source: KFF survey data, state Medicaid bulletins, CMS enrollment
- In the West, only 1.2% of adult Medicaid enrollees have a coverage pathway — Utah is the only covering state, and its funding is limited to FY 2026. California dropped coverage in January 2026. Source: The RX Index regional analysis
- The CMS BALANCE Model may expand Medicaid GLP-1 access in participating states. State applications are due July 31, 2026. No finalized participant list has been published as of April 7, 2026. Source: CMS BALANCE Model documentation
The Coverage Gap
The Coverage Reach metric weights state-level coverage status by adult Medicaid enrollment to show how many low-income Americans actually have a pathway to GLP-1 obesity medications — not just how many states have a policy on paper.
Regional Breakdown
| Region | Adult Enrollees | With Coverage Pathway | Coverage Reach | Covering States |
|---|---|---|---|---|
| Midwest | 7,940,374 | 3,319,373 | 41.8% | Kansas, Michigan, Minnesota, Missouri, Wisconsin |
| South | 9,958,030 | 3,217,926 | 32.3% | Delaware, Mississippi, North Carolina, Tennessee, Virginia |
| Northeast | 8,570,795 | 1,073,516 | 12.5% | Massachusetts, Rhode Island |
| West | 13,054,318 | 160,472 | 1.2% | Utah (restricted, FY 2026 funding only) |
Coverage Changes (Last 12 Months)
Nine states changed their GLP-1 obesity coverage status in the past 12 months. More states dropped coverage (4) than added it (3), with 2 additional states restricting or reinstating coverage. The net effect: 13.8 million adult Medicaid enrollees — 35% of the national total — were affected.
| State | Change | Date | Adult Enrollment Affected | Detail |
|---|---|---|---|---|
| California | Dropped | Jan 2026 | 8,046,081 | Eliminated GLP-1 obesity coverage, likely tied to budget pressure |
| Pennsylvania | Dropped | Jan 2026 | 1,583,396 | Eliminated GLP-1 obesity coverage; still covers some non-GLP-1 weight-loss drugs |
| North Carolina | Reinstated | Dec 12, 2025 | 1,439,212 | Reinstated coverage for FFS and managed care; reverted to Sept 30, 2025 formulary |
| Massachusetts | Restricted | Mar 12, 2026 | 894,026 | Tightened management; Wegovy and Zepbound continue with approved PAs only |
| Missouri | Added | By Oct 1, 2025 | 678,096 | Added Zepbound only for obesity indication |
| Tennessee | Added | By Oct 1, 2025 | 573,328 | Added Wegovy, Zepbound, and Saxenda with prior authorization |
| South Carolina | Dropped | Jan 2026 | 372,512 | Eliminated coverage; had previously covered Saxenda and Wegovy |
| Utah | Added | By Oct 1, 2025 | 160,472 | Added Saxenda, Wegovy, and Zepbound; funding limited to FY 2026 |
| New Hampshire | Dropped | Jan 2026 | 88,816 | Eliminated GLP-1 obesity coverage; still covers some non-GLP-1 weight-loss drugs |
50-State Coverage Table
| State | Obesity Coverage (FFS) | Prior Auth | Key PA Criteria | Drugs on Formulary | BALANCE Status | Recent Change | Adult Enrollment | Source |
|---|
CMS BALANCE Model & Medicare GLP-1 Bridge
BALANCE Model (Medicaid)
The CMS BALANCE Model allows participating states to receive support for expanding Medicaid GLP-1 coverage. Medicaid participation can begin as early as May 2026. State applications are due no later than July 31, 2026, with state agreements executed by January 1, 2027. As of April 7, 2026, no states have publicly announced participation in reviewed sources. The model runs through December 2031.
Participation is voluntary. The model does not guarantee coverage for any individual, and terms depend on negotiations between CMS, manufacturers, and states.
Source: CMS BALANCE Model →
Medicare GLP-1 Bridge
The Medicare GLP-1 Bridge is a nationwide short-term demonstration running from July 1, 2026 through December 31, 2026. Eligible Medicare Part D beneficiaries can access certain GLP-1 medications for weight loss at a $50 monthly copay. Participating manufacturers supply eligible drugs at a net price of $245 per monthly supply to CMS.
Outside of the Bridge and future BALANCE participation, Medicare Part D remains prohibited from covering drugs when used specifically for weight loss.
Source: CMS Medicare GLP-1 Bridge →
Methodology & Limitations
Coverage Status
State Medicaid GLP-1 coverage status was determined using the following source hierarchy:
- KFF Medicaid Coverage of and Spending on GLP-1s tracker (baseline classification, January 2026)
- Individual state Medicaid preferred drug lists and formularies (verification and detail)
- State Medicaid bulletins and provider notices (coverage changes)
Where KFF and state formulary data conflicted, the state formulary was treated as authoritative.
Coverage Reach Calculation
Coverage Reach = adult Medicaid enrollment in covering states ÷ total U.S. adult Medicaid enrollment × 100.
Adult Medicaid enrollment: CMS December 2025 Monthly Medicaid & CHIP Enrollment Report, filtered to adults age 19 and older, excluding CHIP-only enrollees. Total 50-state adult enrollment: 39,523,517.
BALANCE Model Status
BALANCE opt-in status is tracked from CMS official announcements. State applications are due July 31, 2026. Until CMS publishes the finalized participant list, all states are listed as "Not yet announced."
Limitations
- This table tracks fee-for-service coverage as the baseline, consistent with KFF methodology. Over 70% of Medicaid beneficiaries receive care through Managed Care Organizations (MCOs), where formulary coverage and prior authorization criteria may differ significantly.
- The Coverage Reach metric uses the phrase "pathway to access" rather than "have access" because coverage status alone does not guarantee a patient can obtain the medication.
- Prior authorization criteria are summarized at a high level. Actual clinical criteria may include additional requirements.
- Medicaid enrollment fluctuates monthly. Figures used are from December 2025.
- Ozempic (semaglutide) is FDA-approved for type 2 diabetes and cardiovascular risk reduction, not for weight management. It is excluded from this obesity coverage analysis.
- This table does not track commercial insurance or employer-sponsored plan coverage.
Corrections & Updates
Found an error? Email research@therxindex.com. All corrections are documented in the changelog.
Downloads
Licensed under CC BY 4.0. Free to use with attribution to The RX Index.